Clinical trial
A Research Study Examining the Use of Olanzapine for the Prevention of Migraine
NCT00203307 · Thomas Jefferson University, Other · Terminated
Key facts
| NCT number | NCT00203307 |
|---|---|
| Title | A Research Study Examining the Use of Olanzapine for the Prevention of Migraine |
| Official title | A Single-Site, Double-Blind, Placebo-Controlled Cross-Over Trial Examining the Safety and Efficacy of Olanzapine Taken Daily for the Prevention of Episodic Migraine. |
| Lead sponsor | Thomas Jefferson University, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Migraine |
| Intervention type | Drug |
| Interventions | Olanzapine during first intervention period and placebo during second intervention period, Placebo during first intervention period, then olanzapine during second intervention period |
| Enrollment | 3 |
| Start date | May 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Aug 25, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: